The latest development in ultrasound from GE Healthcare, its Logiq E9, promises to tap the modality’s true diagnostic potential while exceeding that of ultrasound alone to provide interventional guidance. The ability to merge data from CT and other modalities into a live ultrasound scan distinguishes this new scanner, which began commercial deliveries in September.
The latest development in ultrasound from GE Healthcare, its Logiq E9, promises to tap the modality's true diagnostic potential while exceeding that of ultrasound alone to provide interventional guidance. The ability to merge data from CT and other modalities into a live ultrasound scan distinguishes this new scanner, which began commercial deliveries in September.
E9's Volume Navigation, which continuously updates a volumetric model of a patient constructed from CT or other source with real-time ultrasound data, offers moment-to-moment guidance for interventionalists. But it is the system's architecture and its novel technologies that set the stage for real-time volumetric scanning throughout the body.
Matched with the Agile beamformer that works with the Logiq E9's advanced ESeries transducers, this new architecture delivers unprecedented image quality and uniformity, according to Terri Bresenham, vice president of GE Healthcare's diagnostic ultrasound and IT business.
Increased penetration and sensitivity, made possible in part by a new acoustic amplifier built into the transducers, allow for visualization of structures regardless of their depth in the patient. This is especially important when scanning obese patients, according to Bresenham.
The Agile platform extends high-quality imaging throughout the patient population and body by defining the context of the data to be acquired. Before starting the scan, the user matches a clinical model that establishes the context of the anatomy to be visualized. This model then serves as a guide for algorithms to adjust parameters of the scan to compensate for the interaction between tissues peculiar in those body parts and ultrasound waves.
The Logiq E9 displaces but does not eliminate its predecessor, the Logiq 9, from the GE ultrasound portfolio. An update for the former flagship is planned for late next year.
Buyers are paying between $200,000 and $250,000 for the new flagship, depending on configuration. Increased productivity helps justify the cost. Workflow tools built into the new system streamline routine scans, reducing the time and effort needed to do an exam, according to the company. Packaged into a program called Scan Assistant, these tools minimize the number of keystrokes needed to perform functions.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.